Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial
鼓励处方SGLT2抑制剂和GLP-1受体激动剂以降低2型糖尿病患者的心血管和肾脏风险:一项随机对照试验的理论依据和设计
期刊:American Heart Journal
影响因子:3.5
doi:10.1016/j.ahj.2025.02.007
Haff, Nancy; Horn, Daniel M; Bhatkhande, Gauri; Sung, Meekang; Colling, Caitlin; Wood, Wendy; Robertson, Ted; Gaposchkin, Daniel; Simmons, Leigh; Yang, Judy; Yeh, James; Crum, Katherine L; Hanken, Kaitlin E; Lauffenburger, Julie C; Choudhry, Niteesh K